121 related articles for article (PubMed ID: 20840390)
1. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs.
Cox SR; Lesman SP; Boucher JF; Krautmann MJ; Hummel BD; Savides M; Marsh S; Fielder A; Stegemann MR
J Vet Pharmacol Ther; 2010 Oct; 33(5):461-70. PubMed ID: 20840390
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of mavacoxib in osteoarthritic dogs.
Cox SR; Liao S; Payne-Johnson M; Zielinski RJ; Stegemann MR
J Vet Pharmacol Ther; 2011 Feb; 34(1):1-11. PubMed ID: 21219337
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review.
Lees P; Pelligand L; Elliott J; Toutain PL; Michels G; Stegemann M
J Vet Pharmacol Ther; 2015 Feb; 38(1):1-14. PubMed ID: 25413929
[TBL] [Abstract][Full Text] [Related]
4. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.
Timchalk C; Nolan RJ
Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410
[TBL] [Abstract][Full Text] [Related]
7. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dirlotapide in the dog.
Merritt DA; Lynch MP; King VL
J Vet Pharmacol Ther; 2007 Aug; 30 Suppl 1():24-32. PubMed ID: 17567512
[TBL] [Abstract][Full Text] [Related]
9. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
10. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
16. Effect of dietary fat on oral bioavailability of tepoxalin in dogs.
Homer LM; Clarke CR; Weingarten AJ
J Vet Pharmacol Ther; 2005 Jun; 28(3):287-91. PubMed ID: 15953202
[TBL] [Abstract][Full Text] [Related]
17. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography-mass spectrometry method: a study on bioavailability and dose proportionality.
Sun J; Zhang L; Song J; Tian S; Huang C; Feng Z; Lv Y; Du G
J Ethnopharmacol; 2013 Jul; 148(2):617-23. PubMed ID: 23707334
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T
Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs.
Vanapalli SR; Hung YP; Fleckenstein L; Dzimianski MT; McCall JW
Biopharm Drug Dispos; 2002 Oct; 23(7):263-72. PubMed ID: 12355577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
